Chugai Pharmaceutical Co., Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Osamu Okuda
- Full Time Employees
- 7,872
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Nihonbashi Mitsui Tower Tokyo SH Japan 103-8324
- IPO Date
- Mar 3, 1956
- Website
- chugai-pharm.co.jp
- Similar Companies
- Business
- Chugai Pharmaceutical Co., Ltd. (4519.T) is a research-oriented pharmaceutical company that develops, manufactures, markets, imports and exports prescription pharmaceuticals, with a primary focus on oncology, immunology, neurology, nephrology, ophthalmology and other specialty areas; its core products include oncology therapies such as Alecensa (alectinib, ALK inhibitor), Avastin (bevacizumab, anti-VEGF humanized monoclonal antibody), Herceptin (trastuzumab, anti-HER2 humanized monoclonal antibody), Kadcyla (trastuzumab emtansine, anti-HER2 antibody-tubulin polymerization inhibitor conjugate), Lunsumio (mosunetuzumab, anti-CD20/CD3 humanized bispecific antibody), Perjeta (pertuzumab, anti-HER2 humanized monoclonal antibody), Phesgo (pertuzumab, trastuzumab and vorhyaluronidase alfa combination), Polivy (polatuzumab vedotin, antimicrotubule binding anti-CD79b monoclonal antibody) and Tecentriq (atezolizumab, anti-PD-L1 humanized monoclonal antibody), as well as FoundationOne CDx and FoundationOne Liquid CDx cancer genomic profiles; in specialty areas, key offerings comprise Actemra (tocilizumab, humanized anti-human IL-6 receptor monoclonal antibody), Enspryng (satralizumab, pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody), Hemlibra (emicizumab, anti-coagulation factor IXa/X humanized bispecific monoclonal antibody), PiaSky (crovalimab, pH-dependent binding humanized anti-complement C5 monoclonal antibody), Vabysmo (faricimab, anti-VEGF/anti-Ang-2 bispecific antibody), Evrysdi (risdiplam, spinal muscular atrophy agent), Mircera (epoetin beta pegol, long-acting erythropoiesis-stimulating agent) and Tamiflu (oseltamivir, anti-influenza agent), among others like CellCept (mycophenolate mofetil, immunosuppressant) and Edirol (eldecalcitol, osteoporosis agent). Founded on March 10, 1925 and formally established in 1943, Chugai is headquartered at 1-1 Nihonbashi-Muromachi 2-chome, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, Japan, and operates primarily in Japan with international presence through subsidiaries including Chugai Pharma Europe in London, UK, and Chugai Pharma China Co., Ltd. in China; it is a majority-owned subsidiary of Roche Holding Ltd., which holds approximately 61% ownership. Recent major developments include a October 2025 collaboration and license agreement with Rani Therapeutics for oral delivery technology featuring a $10 million upfront payment, potential milestones up to $175 million and single-digit royalties, building on a prior August 2024 research pact; in late October 2025, Chugai announced the acquisition of Renalys Pharma, Inc. as a wholly-owned subsidiary by late November 2025 for a closing payment of 15 billion JPY plus up to 16 billion JPY in regulatory milestones and sales-linked considerations to secure exclusive development and commercialization rights for sparsentan (FILSPARI) targeting IgA nephropathy in Japan, South Korea and Taiwan; this is followed by a planned absorption-type merger with Renalys Pharma effective December 29, 2025, to streamline operations and accelerate sparsentan development alongside Chugai's existing IgA nephropathy asset sefaxersen (RG6299).
Company News
Financial Analysis: Chugai Pharmaceutical (OTCMKTS:CHGCY) & Theravance Biopharma (NASDAQ:TBPH)
Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 52-Week Low – Should You Sell?
Analyzing Chugai Pharmaceutical (OTCMKTS:CHGCY) & Ascend Wellness (OTCMKTS:AAWH)
Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume – Here’s What Happened
Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s What Happened
Short Interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Decreases By 54.9%
Chugai Pharmaceutical Co., Ltd. (CHGCY) Q2 2026 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCY) Q1 2026 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2025 Earnings Call Transcript
Chugai Pharmaceutical Co. (CHGCY) Upgraded to Buy: Here's Why
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q4 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's What You Should Know
3 Stocks to Consider with Earnings Approaching